Moreover, this type of immune-associated diabetes occurs more frequently in patients receiving anti-PD-1/PD-L1 than in those treated solely with anti-CTLA-4, indicating that T1DM is primarily associated with anti-PD-1/PD-L1 immunosuppressive therapy. The gene discussed is PDCD1; the disease is type 1 diabetes mellitus.